BRD2 and ovarian cancer: Then, the plasmids were loaded into a drug delivery system, namely an FSH peptide-conjugated polyethylene glycol (PEG)-polyethylenimine (PEI) copolymer that we previously developed, to target FSHR-expressing ovarian cancer cells.